Pharm D Solutions Recalls Bi-Mix Injectable Due to Sterility Concerns
Pharm D Solutions is recalling 29 vials of Bi-Mix (Papaverine/Phentolamine) injectable and powder nationwide due to a lack of assurance of sterility.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this recall as Class II, and the rubric specifies that FDA Class II recalls involving significant injury or property damage reports, or structural defects, are rated as Severe (4). While no specific injuries are reported in the text, the lack of sterility assurance in an injectable drug presents a significant risk of infection, aligning with the Severe category for high-risk medical products.
Plain-English summary
Pharm D Solutions, LLC is recalling 29 vials of Bi-Mix (Papaverine/Phentolamine 150 mg/5 mg) injectable and lyophilized powder. The recall is being conducted because of a lack of assurance of sterility. The affected product is distributed nationwide.
The recall includes specific lots of the injectable and powder forms, identified by lot numbers 04032018, 05242018, 06192018, and 06132018, with corresponding discard-by dates ranging from September 30, 2018, to December 16, 2018. The FDA has classified this recall as Class II.
Healthcare providers and patients should stop using the affected lots of Bi-Mix and contact Pharm D Solutions for further instructions or a replacement. Consumers should verify the lot numbers and discard-by dates on their product packaging against the information provided in this recall notice.
The recalled product
- Product
- Bi-Mix (Papaverine/Phentolamine 150 mg/5 mg) a) Injectable NDC 69699-1760-15; b) (LYO) Powder NDC 69699-1760-15, Pharm D Solutions, Houston, Texas
- Manufacturer
- Pharm D Solutions, LLC
- Category
- Drug — Injectable
- Affected units
- 29
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lots: a)04032018:49 Discard by: 9/30/2018
- 05242018:72 Discard by: 11/20/2018
- b) 06192018:08 Discard by: 12/16/2018
- 06132018:29 Discard by: 12/10/2018
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 79 recalled by Pharm D Solutions, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 79 products in this recall →Related recalls
Same manufacturer · Pharm D Solutions, LLC
See all →- SeverePharm D Solutions Recalls Sermorelin/GHRP-2 &6 Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Sermorelin Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls B-Complex Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SevereFDA Recalls Ipamorelin Acetate Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharm D Solutions Recalls Testosterone Cypionate Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29